HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beiersdorf Shuffling Top Management As Nivea Growth Slows

This article was originally published in The Rose Sheet

Executive Summary

Speculation has it that strategic disagreement between CEO Stefan Heidenreich and Beiersdorf’s controlling Herz family may be the reason for the exec’s planned departure at the end of 2018, if not earlier. The firm also welcomed a new CFO at the start of July after forecasting slowing growth for the remainder of fiscal 2018.

You may also be interested in...



Beiersdorf Making Strategic Moves In Natural Skin Care, China, Digital; Better Late Than Never?

The German firm’s sales increased 6% over the first nine months of fiscal 2019, led by La Prairie luxury, but its mass-market business remains a strategic priority. Bigger digital investments, natural skin-care launches and a sharpened focus on Nivea development in China should help spur growth in the segment.

Beiersdorf Targets 3%-4% Growth In FY 2017 Via ‘Full Speed’ Innovation

The German firm’s “innovation engine is finely tuned and is running on full speed,” according to CEO Stefan Heidenreich. New Nivea sun-care products with Clothing Protection are expected to make a splash, while men’s needs “will be at the heart of all global business activities in 2017,” he noted during the firm’s fiscal 2016 year-end earnings call.

Beiersdorf CEO Signs Five-Year Contract Following Strong 2013

Beiersdorf CEO Stefan Heidenreich has signed a new five-year contract extending his tenure through 2019, the Hamburg, Germany-based firm announces in conjunction with the release of its preliminary Q4/full year 2013 results. Sales rose more than 7% organically to more than $8 billion, though the results on a nominal sales basis were weighted down by currency effects.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121702

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel